AstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Lynparza in pancreatic cancer, extending the drug’s use into a third type of solid tumour. The US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback